WuXi Celebrates Partnerships & Innovation During BIO 2017 Cruise Around San Diego Bay

WuXi celebrated global innovation with hundreds of leaders from biotech, pharma, research institutions, and the venture capital community who attended BIO 2017 during a private cruise reception around San Diego Bay on...

WuXi NextCODE AI Points to New Therapeutic Approaches to Cardiovascular Disease and Cancer in...

We are thrilled about WuXi NextCODE's contribution of its artificial intelligence (AI) and sequencing teams to the discovery of a novel mechanism regulating how blood vessels grow. The study, 'FGF-dependent metabolic control...

WuXi AppTec Completes Acquisition of HD Biosciences

We are pleased to announce WuXi has completed the acquisition of HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO). Shanghai-based HD Biosciences' plate-based pharmacology and screening capability...
video

WuXi Global 2017 Forum Recap

More than 1,500 industry leaders gathered at the WuXi Global Forum 2017. The annual event, held in San Francisco during the J.P. Morgan Healthcare Conference on Jan. 10, promotes new thinking...

WuXi NextCODE Raises $75 Million in Series B Financing to Accelerate Growth of Global...

WuXi would like to congratulate WuXi NextCODE for raising $75 million in Series B financing, led by the company's current investors Temasek and Yunfeng Capital. WuXi NextCODE will focus the use of proceeds...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS

Inside Perspectives on Gene Editing: An Interview with Agenovir CEO Dirk...

Using its deep virology expertise and targeted genome editing technologies, Agenovir is on a mission to develop novel antiviral therapeutics, bringing hope to millions of patients...